1. Pink Sheet

‘Decentralized Clinical Trials 2.0’ On The Horizon

 
• By Vibha Sharma

The remarkable shift towards decentralized clinical trials in the last three years is a testament to how this patient-centric approach of doing research has the potential to solve multiple issues such as time, cost and low participation rates. In this first segment of a two-part article, the Pink Sheet looks at how innovation in this sector has just begun and we can expect more action ahead. 

Patient at home with mobile treatment
Decentralized Trials Can Make It Convenient For Patients To Take Part In Research • Source: Shutterstock

Although the COVID-19 pandemic has contributed to the widespread, systematic adoption of decentralized elements in clinical trials, it is still early days for this new way of conducting research, which allows some or all study-related activities to be conduct in or near a patient’s home.

A lot more activity is expected in this field over the next three to five years, says Craig Lipset, co-founder of the Decentralized Trials & Research Alliance (DTRA), a multi-stakeholder group that took shape amid the coronavirus pandemic to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pink Sheet Perspectives

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.